Mark Kieran
About Mark Kieran
Mark Kieran is the Pediatric Clinical Trial Lead at Bristol Myers Squibb and the VP of Clinical Development at Day One Biopharmaceuticals, with extensive experience in pediatric oncology and immunology.
Title
Mark Kieran holds the position of Pediatric Clinical Trial Lead and serves as the Vice President of Clinical Development at Day One Biopharmaceuticals in Philadelphia, Pennsylvania. In addition, he works as the Pediatric Clinical Trial Lead at Bristol Myers Squibb.
Education and Expertise
Mark Kieran has an extensive educational background. He obtained a Bachelor of Science (BS) in Biochemistry from McMaster University. He then achieved a Doctor of Philosophy (PhD) in Immunology from the University of Alberta. He earned his Doctor of Medicine (MD) from the University of Calgary, School of Medicine. He completed a Postdoctoral Fellowship in Molecular Biology at Pasteur Institute. He underwent a Pediatric Residency at McGill University. He completed a Pediatric Hematology/Oncology Fellowship and a Post-Doctoral Fellowship in Signal Transduction at Harvard Medical School - Boston Children's Hospital.
Professional Background
Mark Kieran has worked at various reputable institutions. He served as the Director of Pediatric Neuro-Oncology at Dana-Farber Boston Children's Blood and Cancer Center for 21 years. He moved to Bristol Myers Squibb in 2018, focusing on pediatric initiatives and combination therapies in oncology. He gained experience in regulatory oversight, medical affairs, global planning, and product commercialization. In July 2021, he joined Day One Biopharmaceuticals, a start-up focused on pediatric oncology. Prior to this, he worked at Celgene, contributing to different roles related to patient safety and medication use.
Achievements
Mark Kieran developed and led a multi-disciplinary program at Dana-Farber Cancer Institute, integrating diverse clinical and laboratory programs from within and outside the Harvard Medical School system. He has been the principal investigator or collaborator on over 100 clinical trials. His work includes implementing Risk Evaluation and Mitigation Strategies (REMS) for medications like Revlimid, Pomalyst, and Thalomid. He is committed to patient safety, equitable access to investigational medicines, and innovative treatments for immune-mediated diseases.
Focus Areas and Initiatives
Mark Kieran is involved in regulatory oversight, patient safety, and the implementation of REMS programs. His current focus is on pediatric oncology and combination therapies in oncology. He also engages in efforts to improve access to investigational medicines, works with physicians to assess individual patient cases, and advocates for increased education on the clinical presentation of diseases like psoriasis across all skin colors.